London, ON – 23 September 2020 – Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announced that the first subjects have been dosed in a two-part, Phase I, first-in-human, safety and pharmacokinetic trial of a once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels) in Type 1 Diabetics.
“This is an exciting day for us. Kicking off a study during a pandemic has its challenges, but we’ve built something really special with the Sponsor and the site that enabled us to get the study up and running and the first dose delivered on time,” said Urszula Bartlomiejska, Project Manager, Stiris Research Inc.
This targeted milestone was achieved on target during the COVID-19 pandemic which has substantial impact on sites and patients alike. “Being able to achieve this milestone for the Sponsor has a significant overall impact on their Diabetes program, and I am thrilled our collective team was able to achieve this,” said Amanda Carrera, Vice President, Stiris Research.
About Stiris Research
Stiris Research is an entrepreneurial Clinical Trial Management company specializing in conducting complex Phase I through IIIB trials for North American biotechnology and biopharmaceutical companies, with a focus on Oncology, CNS and Neurology. Stiris Research was formed as a result of listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs.
For more information, please contact: